Table 1 GLP-1 receptor agonists: cardiovascular indications and CVOTs results

Cardiovascular indication

No

Yes

Reduction of MACEs in adults with T2DM and established CVD

No

No

Yes

Reduction of MACEs in adults with T2DM and established CVD

Yes

Reduction of MACEs in adults with T2DM and established CVD or multiple CV risk factors

No

CVOT [reference]

PIONEER 6 [40]

SUSTAIN 6 [57]

ELIXIA [106]

EXSCEL [107]

LEADER [22]

REWIND [108]

HARMONY [54]

Study population

3183 T2DM patients with established CVD

3297 T2DM patients with established CVD

6068 T2DM patients with acute coronary event in the last 180 days

14,752 T2DM patients with and without established CVD

9340 T2DM patients with established CVD

3183 T2DM patients with established CVD

9463 T2DM patients with established CVD

Intervention

Oral semaglutide 14 mg once a day vs. placebo

Semaglutide 0.5–1.0 mg sc once a week vs. placebo

Lixisenatide 20 μg sc once a day vs. placebo

Exenatide 2.0 mg sc once a week vs. placebo

Liraglutide 1.8 mg sc once a day vs. placebo

Dulaglutide 1.5 mg sc once a week vs. placebo

Albiglutide 30–50 mg sc once a week vs. placebo

Median follow-up

15.9 months

2.1 years

25 months

3.2 years

3.8 years

5.4 years

1.6 years

Primary endpoint: HR; 95%CI; superiority p-value

0.79; 0.57–1.11; p = 0.17

0.74; 0.58–0.95; p = 0.02

1.02; 0.89–1.17; p = 0.81

0.91; 0.83–1.00; p = 0.06

0.87; 0.78–0.97; p = 0.01

0.88; 0.79–0.99; p = 0.026

0.78; 0.68–0.90; p = 0.0006